• RXO, Inc. has reported past first-quarter 2026 results, with sales of US$1,425 million versus US$1,433 million a year earlier and a net loss of US$36 million compared with US$31 million previously.
• The combination of slightly lower revenue and a wider net loss highlights ongoing profitability pressures despite relatively stable top-line performance.
• We’ll explore how the wider quarterly net loss shapes RXO’s existing investment narrative built around technology, diversification, and margin improvement.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

RXO Investment Narrative Recap

To own RXO, you need to believe its technology, LTL mix shift, and new services can eventually turn persistent losses into sustainable profits. The latest quarter’s slightly lower sales and wider net loss keep the spotlight on the near term catalyst of margin improvement and heighten the main risk that ongoing freight and auto sector softness could prolong unprofitability, but the news does not appear to fundamentally change that core debate.

Among recent announcements, the launch of RXO Middle Mile Solutions in February 2026 looks most relevant here. It ties directly into RXO’s effort to stitch together first, middle, and last mile into a single tech-enabled network, which sits at the heart of the margin and growth catalyst investors are watching, even as near term earnings remain under pressure.

But the bigger concern investors should be aware of is how prolonged freight softness could interact with RXO’s limited cash runway and...

RXO's narrative projects $6.6 billion revenue and $86.7 million earnings by 2029. This requires 4.9% yearly revenue growth and a $186.7 million earnings increase from -$100.0 million today.

Uncover how RXO's forecasts yield a $15.85 fair value, a 15% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming RXO could reach about US$7.6 billion of revenue and US$185.6 million of earnings, yet Q1’s wider loss and tech execution risks highlight how differently you and other investors might view RXO’s path from here.

Explore 3 other fair value estimates on RXO - why the stock might be worth 15% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your RXO research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free RXO research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate RXO's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.